(Q36579101)

15 August 2017

Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study (English)

1 reference

15 August 2017

Roberta De Angelis

2

0 references

Milena Sant

object named as

Milena Sant

14

0 references

Rafael Marcos-Gragera

object named as

Rafael Marcos-Gragera

3

0 references

Risto Sankila

11

object named as

Risto Sankila

1 reference

15 August 2017

Marc Maynadié

1

1 reference

15 August 2017

Otto Visser

4

1 reference

15 August 2017

Claudia Allemani

5

1 reference

15 August 2017

Carmen Tereanu

6

1 reference

15 August 2017

Riccardo Capocaccia

7

1 reference

15 August 2017

Adriano Giacomin

8

1 reference

15 August 2017

Jean-Michel Lutz

9

1 reference

15 August 2017

Carmen Martos

10

1 reference

15 August 2017

Tom Børge Johannesen

12

1 reference

15 August 2017

Arianna Simonetti

13

1 reference

15 August 2017

HAEMACARE Working Group

15

1 reference

15 August 2017

14 September 2012

1 reference

15 August 2017

1 reference

15 August 2017

98

1 reference

15 August 2017

2

1 reference

15 August 2017

230-238

1 reference

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France)

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Part I: Milestones in personalised medicine--imatinib

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

A specialist leukaemia/lymphoma registry in the UK. Part 1: Incidence and geographical distribution of Hodgkin's disease. Leukaemia Research Fund Data Collection Study Group

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Variation in survival of adult patients with haematological malignancies in Europe since 1978. EUROCARE Working Group

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

The cancer survival gap between elderly and middle-aged patients in Europe is widening

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Trends in leukemia incidence and survival in the United States (1973–1998)

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

The relative survival rate

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

Cancer survival corrected for heterogeneity in patient withdrawal.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561430

De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance

20 September 2018

1 reference

12 December 2020

Myelodysplastic syndromes: incidence and survival in the United States

1 reference

12 December 2020

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

12 December 2020

Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients

1 reference

12 December 2020

The relative survival rate: a statistical methodology

1 reference

12 December 2020

An alternative approach to monitoring cancer patient survival

1 reference

12 December 2020

[Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004]

1 reference

12 December 2020

The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England

1 reference

12 December 2020

Epidemiology of monoclonal gammopathy in Cote d'Or, France

1 reference

12 December 2020

10.3324/HAEMATOL.2012.064014

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

22983589

1 reference